Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.
Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.
复制标题
DOI：
10.1111/jth.15282
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
NIH COPD Clinical Research Network, the Canadian Institute of Health Research Investigators
中科院分区：
文献类型：
--
作者：
Rao AK;Del Carpio-Cano F;Janapati S;Zhao H;Voelker H;Lu X;Criner G;NIH COPD Clinical Research Network, the Canadian Institute of Health Research Investigators
Statins are widely used to lower lipids and reduce cardiovascular events. In vitro studies and small studies in patients with hyperlipidemias show statins inhibit tissue factor (TF) and blood coagulation mechanisms. We assessed the effects of simvastatin on TF and coagulation biomarkers in patients entered in STATCOPE, a multicenter, randomized, placebo-controlled trial of simvastatin (40 mg daily) versus placebo on exacerbation rates in patients with chronic obstructive pulmonary disease (COPD). In 227 patients (114 simvastatin; 113 placebo; mean (±SEM) age 62 ± 0.53 years, 44.5 % women) we measured (baseline; 6 and 12 months): whole blood membrane TF-procoagulant activity (TF-PCA) and plasma factors VIIa, VII, VIII, fibrinogen, TF antigen, tissue factor pathway inhibitor (TFPI), thrombin-antithrombin complexes (TAT) and D-dimer. We excluded patients with diabetes, cardiovascular disease and those taking or requiring a statin. In the statin group, there was a small increase in TF-PCA (from 25.18±1.08 to 30.36±1.10 U/ml; p=0.03) over 12 months; factors VIIa and VIII, fibrinogen, TAT and D-dimer did not change. Plasma TFPI (from 52.4±1.75 to 44.7±1.78 ng/mL; p< 0.0001) and FVIIC (1.23±0.04 to 1.15±0.03 U/mL; p=0.03) decreased and correlated with total cholesterol levels. No changes in biomarkers were observed with placebo. In contrast to previous studies on statins, in COPD patients without diabetes, cardiovascular disease or requiring a statin treatment, simvastatin (40 mg per day) did not decrease TF or factors VIIa and VIII, fibrinogen, TAT or D-dimer. The decreases in TFPI and factor VII reflect the decrease in serum lipids.
登录
查看更多内容
DOI：
10.1590/s1806-37132014000100006
发表时间：
2014-01
期刊：
Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
影响因子：
--
作者：
Akpinar EE;Hoşgün D;Akpinar S;Ataç GK;Doğanay B;Gülhan M
通讯作者：
Gülhan M
影响因子：
10.4
作者：
Adams, N. B.;Lutsey, P. L.;Cushman, M.
通讯作者：
Cushman, M.
影响因子：
6.7
作者：
Gentile, Nina T.;Vaidyula, Vijender R.;Rao, A. Koneti
通讯作者：
Rao, A. Koneti
影响因子：
158.5
作者：
Ridker, Paul M.;Danielson, Eleanor;Glynn, Robert J.
通讯作者：
Glynn, Robert J.
影响因子：
5.8
作者：
Boden, Guenther;Vaidyula, Vijender R.;Rao, A. Koneti
通讯作者：
Rao, A. Koneti